Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating treatments for newly diagnosed multiple myeloma in patients who cannot undergo autologous stem cell transplantation. This Phase 3 study compares two drug combinations belantamab mafodotin with lenalidomide and dexamethasone BRd versus daratumumab with lenalidomide and dexamethasone DRd. The goal is to see if BRd extends progression-free survival and improves minimal residual disease negative status compared to DRd. Participants receive either BRd or DRd treatment, continuing until disease progression, death, unacceptable side effects, withdrawal, or study end. Both treatment arms involve the administration of lenalidomide and dexamethasone alongside either belantamab mafodotin or daratumumab. Treatment duration may last up to approximately seven years. During the study, participants will undergo regular assessments including monitoring disease progression, response to treatment, and side effects. Measurements include progression-free survival, overall survival, and the number achieving minimal residual disease negative status. Quality of life questionnaires and blood tests will also be conducted. Safety monitoring includes eye exams and tracking adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of MB-CART2019.1 compared to standard treatments in adults with relapsed or refractory diffuse large B-cell lymphoma DLBCL who are not eligible for intensive chemotherapy and stem cell transplantation. The study is a pivotal Phase II randomized, multi-center, open-label trial with two parts Part I compares MB-CART2019.1 to standard therapy, while Part II evaluates MB-CART2019.1 alone in younger, fitter patients. MB-CART2019.1 is a genetically modified T-cell therapy designed to target malignant B cells in advanced blood cancers. Participants in Part I are randomly assigned to receive either a single infusion of MB-CART2019.1 following lymphodepleting chemotherapy or standard of care SoC therapy, which includes regimens like R-GemOx or BR plus polatuzumab vedotin. Patients undergo leukapheresis to collect T cells for MB-CART2019.1 production. Those in the SoC arm may later receive MB-CART2019.1 if certain disease progression criteria are met. Part II will enroll younger participants to receive MB-CART2019.1 alone after Part I enrollment completes. Participants will be involved in screening, treatment, and follow-up visits totaling about 55 weeks. Assessments include scans, laboratory tests, and evaluations of disease response and safety. Primary outcomes measure event-free survival in Part I and objective response rate in Part II, both up to 30 weeks after treatment. Secondary outcomes include progression-free survival, overall survival, and duration of response assessed up to nearly two years. Extended long-term follow-up beyond the active study period will be reported separately.
Actively Recruiting
Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
Actively Recruiting
Researchers are evaluating the GRADY prediction models, which use machine learning to estimate the risk of gram-negative bacteremia and sepsis in intensive care unit ICU patients. Sepsis is a serious condition with high mortality that needs early diagnosis and treatment. Current methods like blood cultures take time, and existing scoring systems such as SOFA, SIRS, and NEWS2 may not detect sepsis early enough. This study aims to compare the GRADY models with these standard scoring systems to assess their ability to provide earlier and more accurate risk detection and support timely clinical decisions in critical care. The study will prospectively validate the GRADY models by using routinely collected vital signs and laboratory data from ICU patients. These models will be assessed for their diagnostic accuracy and clinical usefulness compared to existing scores such as SOFA, SIRS, and NEWS2. The study also plans to calculate Pitt Bacteremia Scores to explore relationships with GRADYs risk classifications. This observational study will include ICU patients who have had blood cultures taken as part of their routine care. Participants will be adult ICU patients monitored for at least 48 hours, with blood cultures obtained during their stay. Data collection involves reviewing routine clinical and laboratory information and calculating various scores at admission. The main outcome is detecting gram-negative bacteremia within 28 days. Secondary outcomes include measuring SOFA, SIRS, and NEWS2 scores at admission. The study aims to evaluate the models ability to identify high-risk patients early, potentially improving treatment timing and outcomes in ICU care. The study will run until early 2026.
Actively Recruiting
Researchers are evaluating whether adding revumenib to standard intensive chemotherapy improves outcomes for participants newly diagnosed with acute myeloid leukemia AML who have a specific NPM1 genetic mutation. This Phase 3 study also assesses the safety of combining revumenib with chemotherapy compared to chemotherapy alone. Participants must be eligible for intensive chemotherapy and meet specific health and mutation criteria. Participants will be randomly assigned to one of two groups one group receives revumenib orally combined with an intensive chemotherapy regimen of cytarabine and daunorubicin given by intravenous infusion, while the other group receives a placebo orally with the same chemotherapy regimen. The study is double-blind, so neither participants nor researchers know who receives revumenib or placebo during the trial. Treatment and assessments will continue with regular monitoring. During the study, participants undergo multiple assessments including evaluation of event-free survival and measurable residual disease complete remission rates over up to 2 years. Additional outcomes like overall survival and response rates are tracked up to 5 years. Safety is monitored by recording treatment-emergent adverse events and changes in patient-reported fatigue. Participants will have various clinical visits and laboratory tests throughout the treatment and follow-up periods to evaluate effectiveness and safety.